Evolution of the Average Target: Exelixis, Inc.

Evolution of the Target Price: Exelixis, Inc.

Changes in Analyst Recommendations: Exelixis, Inc.

997daa6bbc7034.7c6I7bjFVuyET1caFDBGVmd9Iw1MP7J5yexDGMNLkhE.2YzRl92_J721OwB-V18KEDA1Fjp4bPU9ho4hS6YY6l2sudyyj4AQ2sUnAg~108bfe8f1ebf8e36677173fda64fea16
05-06 Exelixis Seen Trading Steady on Modest Drug Growth, RBC Says MT
03-02 RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating MT
02-11 RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating MT
02-02 Morgan Stanley Lifts Price Target on Exelixis to $49 From $48, Keeps Overweight Rating MT
01-14 Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating MT
01-08 Exelixis Shares Fall After Downgrade From Morgan Stanley MT
01-08 Morgan Stanley Downgrades Exelixis to Equalweight, Price Target is $48 MT
01-05 Exelixis Faces Limited High-Impact Catalysts, BofA Says MT
01-05 BofA Securities Downgrades Exelixis to Underperform From Neutral, Adjusts Price Target to $41 From $43 MT
11-06 UBS Adjusts Price Target on Exelixis to $40 From $35, Maintains Neutral Rating MT
11-05 Morgan Stanley Lifts Price Target on Exelixis to $45 From $44, Keeps Overweight Rating MT
11-03 Exelixis Shares Fall After Guggenheim Downgrade MT
11-03 Guggenheim Downgrades Exelixis to Neutral From Buy MT
25-10-21 Exelixis Shares Rise After Leerink Partners Upgrade MT
25-10-21 Leerink Partners Upgrades Exelixis to Outperform From Market Perform, Adjusts Price Target to $48 From $38 MT
25-10-18 Exelixis, Inc. Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating Cabozantinib in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 CI
25-07-30 UBS Adjusts Price Target on Exelixis to $38 From $43, Maintains Neutral Rating MT
25-07-29 Analyst recommendations: Blackstone, Airbnb, Amphenol, Cadence Design Systems, Ameriprise Financial... Zonebourse
25-07-29 RBC Lowers Price Target on Exelixis to $45 From $50, Keeps Sector Perform Rating MT
25-07-29 Truist Cuts Price Target on Exelixis to $49 From $56, Keeps Buy Rating MT
25-07-29 Morgan Stanley Lowers Price Target on Exelixis to $46 From $48, Keeps Overweight Rating MT
25-07-15 Truist Lifts Price Target on Exelixis to $56 From $55, Keeps Buy Rating MT
25-07-08 RBC Downgrades Exelixis to Sector Perform From Outperform, Lifts Price Target to $50 From $45 MT
25-07-07 RBC Raises Price Target on Exelixis to $45 From $40, Keeps Outperform Rating MT
25-06-24 Stephens Upgrades Exelixis to Overweight From Equalweight, Adjusts Price Target to $60 From $29 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-7.77%
+8.05%
+46.39%
+36.71%
+101.96%
+50.93%
+42.87%
+31.9%
-14.59%
+41.17%
Average +33.76%
Weighted average by Cap. +33.82%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
53.13USD
Average target price
49.00USD
Spread / Average Target
-7.77%
High Price Target
62.00USD
Spread / Highest target
+16.69%
Low Price Target
40.00USD
Spread / Lowest Target
-24.71%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
Morgan Stanley
Truist Securities
BofA Securities
UBS
Guggenheim
Leerink Partners
Stephens Inc.
Wells Fargo Securities
Oppenheimer
William O'Neil & Co
BMO Capital
Barclays
BTIG
Citigroup
JMP Securities
SVB Securities LLC
Credit Suisse
EF Hutton
Piper Sandler
Jefferies & Co.
HC Wainwright
Needham & Co.
Goldman Sachs
Wolfe Research
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
53.13USD
Average target price
49.00USD
Spread / Average Target
-7.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock
  4. Consensus Exelixis, Inc.
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!